interferon induced protein with tetratricopeptide repeats 1BGenealiases: IFIT1L · bA149I23.6
Q-omics provides the consensus-scored IFIT1B profile across patient tissues and cancer cell-line models. IFIT1B expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, IFIT1B is differentially expressed in 6, with the highest sampling consensus in LUSC. Additionally, IFIT1B RNA expression shows 11,092 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SCLC, LUSC, and UVM as cancer lineages where IFIT1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFIT1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFIT1B survival associations across molecular data types. IFIT1B RNA expression shows survival associations in the most cancer types (17), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFIT1B RNA expression–survival associations across cancer types. High IFIT1B expression shows unfavorable associations in SCLC, UVM and ACC, but favorable associations in KIRC, SKCM and ESCA. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for IFIT1B RNA expression.
This table summarizes IFIT1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 1. The strongest signals are observed in LUSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IFIT1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFIT1B shows lower tumor expression in LUSC, KICH and UCEC and higher tumor expression in KIRC, BLCA and HNSC. The LUSC box plot shows higher IFIT1B RNA expression in normal versus tumor tissue (log2 FC = −0.084, t-test p < 0.001).
This table shows molecular features associated with IFIT1B in patient tissues and cancer cell lines. In patient samples, IFIT1B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, IFIT1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
